- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02030886
IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients
A Single-center, Open Label, Prospective Study Assessing the 24-hour IOP Patterns Using SENSIMED Triggerfish® in Ocular Hypertensive Patients Newly Converted to Glaucomatous Disease Versus Stable Ocular Hypertensive Patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of OHT (IOP >21 mmHg on 2 consecutive visits) in the study eye
- No IOP-lowering drug treatment in the study eye; otherwise, a 4-week wash-out period prior to study day 0 (SD0) and throughout the study
- Aged ≥ 18 years, of either sex
- Not more than 6 diopters spherical equivalent in the study eye
- Having given written informed consent, prior to any investigational procedures
Exclusion Criteria:
- Narrow iridocorneal angle or any other concomitant ocular conditions (except cataract) in the study eye
- History of ocular surgery on the study eye (except cataract extraction)
- History of laser treatment on the study eye
- Corneal or conjunctival abnormality in the study eye, precluding contact lens adaptation
- Severe dry eye syndrome
- Subjects with irregular sleep schedules
- Subjects who are current smokers
- Subjects with allergy to corneal anesthetic
- Subjects with contraindications for silicone contact lens wear
- Subjects not able to understand the character and individual consequences of the investigation
- Participation in other clinical research within the last 4 weeks
- Any other contra-indication listed in the TF user manual
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Ocular hypertension subjects
All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
|
All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relationship Between Intraocular Pressure (IOP) Pattern as Recorded by TF, and Quantified by Acrophase Scored Dichotomously, and Conversion to Glaucoma in Ocular Hypertension (OHT) Patients (Conversion Status)
Time Frame: 24 hours
|
For each subject, TF acrophase (ie. time when peak occured) was scored dichotomously (before and after 7 am) and compared between OHT converters and non converters patients. One subject was removed from the analysis because of invalid TF output. |
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acrophase Scored Continuously (i.e. Actual Time of TF Peak Occurrence)
Time Frame: 24 hours
|
Mean TF acrophase (ie. actual time when peak occured) was compared between OHT converters and non converters. One subject was removed from the analysis because of invalid TF output. |
24 hours
|
|
Amplitude of Best-fitting Cosine Curve to 24-hour TF Measurements
Time Frame: 24 hours
|
This represents an estimate of the magnitude of 24-hour IOP-related variation.
One subject was removed from the analysis because of invalid TF output.
|
24 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ji Liu, MD, Yale University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TF-1302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Western Galilee Hospital-NahariyaUnknown
-
Joint Shantou International Eye Center of Shantou...CompletedPrimary Angle-Closure Glaucoma | Acute Ocular Hypertension Glaucoma | Intraocular HypertensionChina
-
Medical University of South CarolinaRecruitingOpen-angle Glaucoma (OAG) | Ocular Hypertension (OHT)United States
-
Glaukos CorporationRecruitingOcular Hypertension (OH) | Open Angle Glaucoma (OAG)United States
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
University of PittsburghNational Eye Institute (NEI); West Virginia UniversityRecruitingGlaucoma and Ocular HypertensionUnited States, Canada
-
Qlaris Bio, Inc.RecruitingOAG - Open-Angle Glaucoma | OHT - Ocular HypertensionUnited States
-
Lagos State Health Service CommissionRecruitingPrimary Open Angle Glaucoma or Ocular HypertensionNigeria
-
Santen Inc.Completed
Clinical Trials on Sensimed Triggersfish® (TF)
-
Sensimed AGTerminatedPrimary Open-angle Glaucoma (POAG) PatientUnited States
-
Sensimed AGCompletedSleep Apnea, Obstructive | Primary Open-angle GlaucomaUnited States
-
Sensimed AGClinique MonchoisiTerminatedPrimary Open Angle GlaucomaSwitzerland
-
Sensimed AGCompleted
-
University Hospital, BordeauxCompletedOpen Angle Glaucoma With a Progressive Visual FieldFrance
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Normal Tension GlaucomaPoland
-
Sensimed AGWithdrawn
-
Sensimed AGTerminatedHealthy SubjectsSwitzerland
-
University Hospital, GenevaTerminatedOpen Angle GlaucomaSwitzerland